Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Begin Pilot Study on Drug Risk Management Plans for Generics
October 12, 2012
-
ORGANIZATION Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
-
BUSINESS Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
-
BUSINESS Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
-
ORGANIZATION Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
-
REGULATORY Dr Takenaka Tapped as NIBIO Advisor, Committed to Creation of Drug Discovery Network
October 9, 2012
-
BUSINESS GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
-
BUSINESS Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
-
REGULATORY Senior Vice Minister Sakurai Calls for Industry-Growth Perspective on Long-Listed Drug Pricing
October 4, 2012
-
REGULATORY MHLW to Enhance Drug Review System to Eliminate Application Lag: PFSB Director Gen. Ebata
October 3, 2012
-
REGULATORY Pharmacist Mitsui Becomes Health Minister, Industry Hails Appointment
October 2, 2012
-
BUSINESS Daiichi Sankyo, AZ to Step Up Promotion for Nexium upon Lifting of Long-Term Prescription Ban
October 1, 2012
-
REGULATORY Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
-
BUSINESS Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
-
BUSINESS Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
-
BUSINESS Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
-
ORGANIZATION MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
-
BUSINESS Pfizer Preparing for Assault on Domestic Generic Drug Market with Help from Mylan
September 24, 2012
-
REGULATORY MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
-
ORGANIZATION Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…